Rumblings Over Russia’s COVID-19 Vaccine Approval

Reports Differ Over Immunization Program And Manufacturing

Amid concerns from vaccine experts over Russia’s approval of the first COVID-19 vaccine last week, questions remain over precisely when immunization will begin and the plans for Phase III trials.    

Sputnik V
• Source: Shutterstock

The rapid approval by the Russian health ministry of a vaccine against COVID-19 based on limited human data has provoked disquiet among experts, as confusion reigns over the country’s exact plans for Phase III studies and its mass vaccination program.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By 

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.